Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 25.
doi: 10.1007/s10620-025-09240-3. Online ahead of print.

Gastrointestinal Manifestations of Yao Syndrome (NOD2-Associated Autoinflammatory Disease)

Affiliations

Gastrointestinal Manifestations of Yao Syndrome (NOD2-Associated Autoinflammatory Disease)

John A Damianos et al. Dig Dis Sci. .

Abstract

Background: Yao syndrome (YAOS) is a NOD2-associated autoinflammatory disease characterized by periodic fevers, dermatitis, polyarthritis, swelling of the distal extremities, and gastrointestinal symptoms in patients with specific NOD2 variants. While gastrointestinal symptoms are a hallmark of the disease, little is known about specific symptoms and their underlying mechanisms.

Methods: In this study, we identified 24 patients with YAOS from an institutional YAOS databse. We evaluated their presenting gastrointestinal symptoms at initial presentation via the validated Gastrointestinal Symptom Rating Scale questionnaire, which 14 participants filled out. We then systematically analyzed all gastrointestinal-relevant blood work, stool studies, imaging, endoscopies, and motility testing.

Results: Gastrointestinal symptoms were reported by 100% of patients, with the most prominent symptom being bloating. Most of the workup including stool testing, gastrointestinal-related bloodwork, and endoscopic examinations with biopsies was normal. Abdominopelvic radiographs and cross-sectional imaging studies were most often normal, although an excessive stool burden was commonly identified. A minority of patients had associated diagnoses of collagenous gastritis, celiac disease, autoimmune-like enteropathy, or microscopic colitis. Gastric and colonic motility testing was normal in most patients; however, anorectal manometry with balloon expulsion testing was abnormal in 100% of tested patients. A minority of patients had hepatic steatosis or benign liver lesions.

Conclusions: Gastrointestinal symptoms of YAOS are universal and severe, and symptoms may arise from both inflammatory and non-inflammatory mechanisms. Bloating and constipation may be driven by dyssynergic defecation.

Keywords: Autoimmune; Autoinflammatory diseases; NOD2; Yao syndrome.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: Dr. Damianos receives clinical trial funding and consulting fees from ExeGi Pharma, as well as speakers bureau fees from i-Health. Dr. Davis has research support from Pfizer and has technology licensing agreements with Girihlet and Remission Medical. He has provisional U.S. patent application no. 63/243,933 entitled, “Methods and Materials for Assessing and Treating Arthritis,” which has been licensed to NLC Ventures. Dr. Loftus is a consultant for AbbVie, Alvotech, Amgen, Arena, Avalo, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion Healthcare, Eli Lilly, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iota Biosciences, Iterative Health, Janssen, Morphic, Ono, Protagonist, Sun, Surrozen, Takeda, and UCB. He has research support from AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene/Receptos, Janssen, Takeda, Theravance, and UCB. He is a shareowner of Exact Sciences. Dr. Murray has received research grants from Nexpep/ImmusanT, National Institutes of Health, Immunogenix, Takeda Pharmaceutical, Allakos, ProventionBio, Oberkotter Foundation, and 9 m, Inc.; contract (to institution) from Kanyos Bio (a wholly owned subsidiary of Anokion); and consultancy fees from Johnson and Johnson, Bristol-Myers Squibb, Intrexon Corporation, Dren Bio, Neoleukin, Reistone pharma, Immunic Therapeutics, Senda Biosciences, Brightseed Bio, Chugai Pharma, Alimentiv, Equillium, Ukko, Vial Health Technologies and has received royalties from Torax Medical and Evelo.

References

    1. Yao Q, Zhou L, Cusumano P et al. A new category of autoinflammatory disease associated with NOD2 gene mutations. Arthritis Research & Therapy. 2011;13:148.
    1. Yao Q, Shen B. A systematic analysis of treatment and outcomes of NOD2-associated autoinflammatory disease. The American Journal of Medicine. 2017;130:365.e313-365.e318.
    1. Yang X, Wu D, Li J, Shen M, Zhang W. A Chinese case series of Yao syndrome and literature review. Clinical Rheumatology. 2018;37:3449–3454. - PubMed
    1. Williamson KA, Samec MJ, Patel JA et al. Clinical phenotype, NOD2 genotypes, and treatment observations in Yao syndrome: a retrospective case series. Front Immunol. 2024;15:1304792. - PubMed - PMC
    1. Nomani H, Wu S, Saif A et al. Comprehensive clinical phenotype, genotype and therapy in Yao syndrome. Front Immunol. 2024;15:1458118. - PubMed - PMC

LinkOut - more resources